August 2, 2021
InterVenn and SoftBank Group have officially joined forces in the company's continuing efforts in glycoproteomics research, aimed at improving therapy outcomes for cancer patients. In addition to SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management are participating as new investors in the company. InterVenn thanks everyone for sharing our vision that no one should be blindsided by disease!
— InterVenn
Read the complete article here
June 10, 2021
InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test
— Business Wire, Inc.
Read the complete article here
April 15, 2021
InterVenn Biosciences Announces that Padmanee Sharma, MD, PhD, has Joined the Company’s Board of Advisors
— Odessa American
Read the complete article here
April 15, 2021
InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of Advisors
— BioSpace
Read the complete article here
April 12, 2021
InterVenn’s Glycoproteomic-based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors
— Business Wire, Inc.
Read the complete article here
December 21, 2020
Follow the Money: Decentralized Trials, Stem Cell Research, Stroke Treatment
— Clinical Research News
Read the complete article here
December 7, 2020
P2 Billion Raised: This Filipino CEO's Biotech Startup is Working On Early Detection of Ovarian Cancer
— Esquire
Read the complete article here
November 17, 2020
With a ‘monopoly’ on glycoproteomics, InterVenn raises $34M to push cancer diagnostic into the clinic, woos Illumina BD exec
— San Diego Biotechnology Network
Read the complete article here
November 17, 2020
With a 'Monopoly' on Glycoproteomics, InterVenn Raises $34M to Push Cancer Diagnostic Into the clinic, Woos Illumina BD Exec
— Endpoints News.
Read the complete article here
November 16, 2020
InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer
— Yahoo! Finance
Read the complete article here
November 16, 2020
Intervenn Biosciences Raises $34M To Commercialize Glycoproteomic Ldt For Ovarian Cancer And Immuno-oncology; Taps John Leite, Ph.d., As Chief Business Officer | Business Wire
— Trusted Insight
Read the complete article here
November 16, 2020
InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer
— Yahoo! News
Read the complete article here
November 16, 2020
"InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Tests"
— Genomeweb.
Read the complete article here
November 16, 2020
"InterVenn Biosciences raises $34 million to accelerate cancer test development with AI"
— Venture Beat.
Read the complete article here
November 10, 2020
"InterVenn Biosciences Reports Results on Vista™ : a Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomics"
— Businesswire.
Read the complete article here
November 10, 2020
"InterVenn Biosciences Reports Results on Vista™ : a Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomics"
— Businesswire.
Read the complete article here
October 13, 2020
"InterVenn Biosciences Uses Glycoproteomics to Identify Potential COVID-19 Susceptibility Markers"
— Yahoo Finance.
Read the complete article here
June 22, 2020
"This Week’s AI & Drug Discovery Conference Xcelerating Life Sciences San Francisco Features insitro, Atomwise, twoXAR, InterVenn, Engine Biosciences & More"
— Xconomy, Inc.
Read the complete article here
March 23, 2020
"InterVenn Biosciences Adds Glycoproteomic Clinical Testing Panel for Colorectal Cancer and Advanced Adenoma"
— Business Wire, Inc.
Read the complete article here
February 5, 2020
"InterVenn Biosciences’ Blood Based Test Developed Using Artificial Intelligence Successfully Detects Nasopharyngeal Cancer"
— NAM News Network
Read the complete article here
February 2, 2020
"Meet the Silicon Valley-based Filipino founder fighting to end cancer"
— SparkUp, BusinessWorld Publishing
Read the complete article here
January 13, 2020
"InterVenn Biosciences Expands Work in Glycoproteomics to Successfully Target a Range of Cancers and Other Indications"
— BioSpace
Read the complete article here
January 13, 2020
"InterVenn Biosciences Advances Glycoproteomics to Propel Understanding and Find New Therapies in Complex Diseases"
— Business Wire, Inc.
Read the complete article here
December 4, 2019
"InterVenn Biosciences Releases First-Ever Software for AI-Enabled Mass Spec Analysis"
— Business Wire, Inc.
Read the complete article here
November 18, 2019
"InterVenn Biosciences Announces Positive Interim Clinical Trial Results and Appoints Biotech Veteran Klaus Lindpaintner, M.D. as Chief Scientific and Medical Officer"
— Business Wire, Inc.
Read the complete article here
December 14, 2018
"Top VC deals: Plaid raises at $2.65 billion; The Riveter reels in cash to build coworking spaces for women"
— CNBC LLC
Read the complete article here
December 12, 2018
"The Funded: Plaid's 10X valuation jump tops $450M in midweek deals"
— American City Business Journals
Read the complete article here
December 12, 2018
"InterVenn BioSciences Raises $9.4 Million to Help Physicians Detect Early Ovarian Cancer With a Minimally Invasive Test"
— Business Wire, Inc.
Read the complete article here
